Insulin is needed less frequently and HbA1c is lowered more robustly when adults with type 2 diabetes do not delay combination therapy but begin treatment by taking sitagliptin and metformin together, ...

Sitagliptin (trade names: Januvia and Xelevia) is approved for certain adults with type 2 diabetes mellitus whose blood-glucose levels are inadequately controlled by diet and exercise alone. The fixed ...

With the addition of these two products, Sandoz continues to support diabetic patients and strengthens its leadership position among generic companies in the diabetes therapeutic class products.

These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505 (b) (2) route. The Zituvio range of products contain active ingredients ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin ...

Co says data presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrated that, when used investigationally as initial therapy in combination with metformin, ...

Sitagliptin is prescribed metformin januvia 50mg people who still have high blood sugar, even though they have a sensible diet and exercise regularly. It comes as tablets that you swallow. Common side ...

With the two active components, sitagliptin and metformin, Janumet has a comprehensive mechanism of action that targets all three key defects of T2DM for improved glycemic control: diminished insulin ...

The alert was based on data from three 20-week double-blind, placebo-controlled studies each with 34-week extensions. Sitagliptin does not appear to significantly improve glycemic control in pediatric ...

As a new class of OADs, DPP-4 inhibitors have many important advantages over other currently available antidiabetic drugs. Compared with currently available insulin secretagogues, DPP-4 inhibitors, by ...

AHMEDABAD, India, Jan. 7, 2025 /PRNewswire/ -- Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as 'Zydus'), a global innovation ...